Recommended INN

Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée

Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada

Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada

acidum salclobuzicum

salclobuzic acid

4-(4-chloro-2-hydroxybenzamido)butanoic acid

acide salclobuzique

acide 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoïque

ácido salclobúzico

ácido 4-[(4-cloro-2-hidroxibenzoil)amino]butanoico

C₁₁H₁₂ClNO₄

ancrivirocum

ancriviroc

3-({4-[(Z)-(4-bromophenyl)(ethoxyimino)methyl]-4'-methyl-[1,4'-bipiperidin]-1'-yl}carbonyl)-2,4-dimethylpyridine-1-oxide

ancriviroc

4-[(Z)-(4-bromophényl)(éthoxyimino)méthyl]-1'-[(2,4-diméthyl-1-oxydopyridin-3-yl)carbonyl]-4'-méthyl-1,4'-bipipéridinyle

ancriviroc

4-[(Z)-(4-bromofenil)(etoxiimino)metil]-1'-[(2,4-dimetil-1-oxidopiridin-3-il)carbonil]-4'-metil-1,4'-bipipéridinilo

C₂₈H₃₇BrN₄O₃

aplindorum

aplindore

(2S)-2-[(benzylamino)methyl]-2,3,7,9-tetrahydro-8H-1,4-dioxino=[2,3-e]indol-8-one

aplindore

(2S)-2-[(benzylamino)méthyl]-2,3,7,9-tétrahydro-8H-1,4-dioxino=[2,3-e]indol-8-one

aplindor

(2S)-2-[(bencilamino)metil]-2,3,7,9-tetrahidro-8H-1,4-dioxino=[2,3-e]indol-8-ona

C₁₈H₁₈N₂O₃

atilmotinum

atilmotin

N-[(2S)-3-phenyl-2-(trimethylazaniumyl)propanoyl]-L-valyl-L-prolyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-tyrosylglycyl-L-glutamyl-L-leucyl-L-glutaminyl-D-arginyl-L-leucyl-L-lysinamide

atilmotine

N-[(2S)-3-phényl-2-(triméthylammonio)propanoyl]-L-valyl-L-prolyl-L-isoleucyl-L-phénylalanyl-L-thréonyl-L-tyrosylglycyl-L-glutamyl-L-leucyl-L-glutaminyl-D-arginyl-L-leucyl-L-lysinamide

atilmotina

N-[(2S)-3-fenil-2-(trimetilamonio)propanoil]-L-valil-L-prolil-L-isoleucil-L-fenilalanil-L-treonil-L-tirosilglicil-L-glutamil-L-leucil-L-glutaminil-D-arginil-L-leucil-L-lisinamida

C₈₆H₁₃₄N₂₀O₁₉

avanafilum

avanafil

4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide

avanafil

4-[(3-chloro-4-méthoxybenzyl)amino]-2-[(2S)-2-(hydroxyméthyl)=pyrrolidin-1-yl]-N-(pyrimidin-2-ylméthyl)pyrimidine-5-carboxamide

avanafilo

4-[(3-cloro-4-metoxibencil)amino]-2-[(2S)-2-(hidroximetil)pirrolidin-1-il]-N-(pirimidin-2-ilmetil)pirimidina-5-carboxamida

C₂₃H₂₆ClN₇O₃

balicatibum

balicatib

N-{1-[(cyanomethyl)carbamoyl]cyclohexyl}-4-(4-propylpiperazin-1-yl)benzamide

balicatib

N-[1-[(cyanométhyl)carbamoyl]cyclohexyl]-4-(4-propylpipérazin-1-yl)benzamide

balicatib

N-[1-[(cianometil)carbamoil]ciclohexil]-4-(4-propilpiperazin-1-il)benzamida

C₂₃H₃₃N₅O₂

becatecarinum

becatecarin

1,11-dichloro-6-[2-(diethylamino)ethyl]-12-(4-O-methyl-β-D-glucopyranosyl)-12,13-dihydro-5H-indolo[2,3-a]pyrrolo=[3,4-c]carbazole-5,7(6H)-dione

bécatécarine

1,11-dichloro-6-[2-(diéthylamino)éthyl]-12-(4-O-méthyl-β-D-glucopyranosyl)-12,13-dihydro-5H-indolo[2,3-a]pyrrolo= [3,4-c]carbazole-5,7(6H)-dione

becatecarina

1,11-dicloro-6-[2-(dietilamino)etil]-12-(4-O-metil-?-D-glucopiranosil)-12,13-dihidro-5H-indolo[2,3-a]pirrolo[3,4-c]carbazol-5,7(6H)-diona

C₃₃H₃₄Cl₂N₄O₇

becocalcidiolum

becocalcidiol

(1R,3R)-4-(2-{(1R,3aS,7aR)-1-[(2S)-butan-2-yl]-7a-methyloctahydro-4H-inden-4-ylidene}ethylidene)-2-methylidenecyclohexane-1,3-diol

bécocalcidiol

(1R,3R)-2-méthylidène-5-[(2E)-2-[(1R,3aS,7aR)-7a-méthyl-1-[(1S)-1-méthylpropyl]octahydro-4H-indén-4-ylidène]éthylidène]= cyclohexane-1,3-diol

becocalcidiol

(1R,3R)-2-metilideno-5-[(2E)-2-[(1R,3aS,7aR)-7a-metil-1-[(1S)-1-metilpropil]octahidro-4H-inden-4-ilideno]etilideno]= ciclohexano-1,3-diol

C₂₃H₃₆O₂

bemotrizinolum

bemotrizinol

2,2'-[6-(4-methoxyphenyl)-1,3,5-triazine-2,4-diyl]bis={5-[(2-ethylhexyl)oxy]phenol}

bémotrizinol

2,2'-[6-(4-méthoxyphényl)-1,3,5-triazine-2,4-diyl]bis=[5-[(2-éthylhexyl)oxy]phénol]

bemotrizinol

2,2'-[6-(4-metoxifenil)-1,3,5-triazina-2,4-diil]bis[5-[(2-etilhexil)=oxi]fenol]

C₃₈H₄₉N₃O₅

besilesomabum

besilesomab

immunoglobulin G1, anti-(human CEA (carcinoembryonic antigen)-related antigen) (mouse monoclonal BW 250/183 heavy chain), disulfide with mouse monoclonal BW 250/183 κ-chain, dimer

bésilésomab

immunoglobuline G1, anti-(molécules de l'adhésion cellulaire, antigènes carcinoembryonaires humains (CEA ou CD66)), dimère du disulfure entre la chaîne lourde et la chaîne κ de l'anticorps monoclonal de souris BW 250/183

besilesomab

inmunoglobulina G1, anti-(moléculas de adhesión celular, antígenos carcinoembrionarios humanos (CEA o CD66)), dímero del disulfuro entre la cadena pesada y la cadena κ del anticuerpo monoclonal de ratón BW 250/183

bisoctrizolum

bisoctrizole

2,2'-methylenebis[6-(2H-benzotriazol-2-yl)-4-(2,4,4-trimethylpentan-2-yl)phenol]

bisoctrizole

2,2'-méthylènebis[6-(2H-benzotriazol-2-yl)-4-(1,1,3,3- tétraméthylbutyl)phénol]

bisoctrizol

2,2'-metilenobis[6-(2H-benzotriazol-2-il)-4-(1,1,3,3-tetrametilbutil)=fenol]

C₄₁H₅₀N₆O₂

canfosfamidum

canfosfamide

N-γ-L-glutaminyl-3-(2-{bis[bis(2-chloroethyl)amino]=phosphoryl}ethanesulfonyl)-L-alanyl-(2R)-2-phenylglycine

canfosfamide

acide (2S)-2-amino-5-[[(1R)-1-[[[2-[[bis[bis(2-chloroéthyl)amino]=phosphinoyl]oxy]éthyl]sulfonyl]méthyl]-2-[[(R)-carboxyphénylméthyl]= amino]-2-oxoéthyl]amino]-5-oxopentanoïque

canfosfamida

ácido (2S)-2-amino-5-[[(1R)-1-[[[2-[[bis[bis(2-cloroetil)amino]=fosfinoil]oxi]etil]sulfonil]metil]-2-[[(R)-carboxifenilmetil]amino]-2-oxoetil]amino]-5-oxopentanoico

C₂₆H₄₀Cl₄N₅O₁₀PS

ceftobiprolum

ceftobiprole

(6R,7R)-7-[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)=acetamido]-8-oxo-3-[(E){(3'R)-2-oxo-[1,3'-bipyrrolidin]-3-ylidene}=methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ceftobiprole

acide (6R,7R)-7-[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)=(hydroxyimino)acétyl]amino]-8-oxo-3-[(E)-[(3'R)-2-oxo-1,3'-bipyrrolidinyl-3-ylidène]méthyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylique

ceftobiprol

ácido (6R,7R)-7-[[(2Z)-(5-amino-1,2,4-tiadiazol-3-il)(hidroxiimino)=acetil]amino]-8-oxo-3-[(E)-[(3'R)-2-oxo-1,3'-bipirrolidinil-3-ilideno]metil]-5-tia-1-azabiciclo[4.2.0]oct-2-eno-2-carboxílico

C₂₀H₂₂N₈O₆S₂

ceftobiprolum medocarilum

ceftobiprole medocaril

(6R,7R)-7-[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)=acetamido]-3-[(E){(3'R)-1'-[(5-methyl-2-oxo-1,3-dioxol-4-yl)= methoxycarbonyl]-2-oxo-[1,3'-bipyrrolidin]-3-ylidene}methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ceftobiprole médocaril

acide (6R,7R)-7-[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)=(hydroxyimino)acétyl]amino]-3-[(E)-[(3'R)-1'-[[(5-méthyl-2-oxo-1,3-dioxol-4-yl)méthoxy]carbonyl]-2-oxo-1,3'-bipyrrolidinyl-3-ylidène]méthyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylique

ceftobiprol medocarilo

ácido (6R,7R)-7-[(2Z)-(5-amino-1,2,4-tiadiazol-3-il)(hidroxiimino)=acetamido]-3-[(E)-[(3'R)-1'-[[(5-metil-2-oxo-1,3-dioxol-4-il)metoxi]carbonil]-2-oxo-1,3'-bipirrolidinil-3-ilideno]metil]-8-oxo-5-tia-1-azabiciclo[4.2.0]oct-2-eno-2-carboxílico

C₂₆H₂₆N₈O₁₁S₂

cintredekinum besudotoxum

cintredekin besudotox

toxin hIL13-PE38QQR (plasmid phuIL13-Tx)

cintrédékine bésudotox[Met¹⁷,His¹⁸]précurseur de l'interleukine-13 humaine-(17-132)-peptide (132→246')-protéine avec la dès-Ala³⁶⁵, Asp³⁶⁶, Val³⁶⁷, Val³⁶⁸, Ser³⁶⁹, Leu³⁷⁰, Thr³⁷¹, Cys³⁷², Pro³⁷³, Val³⁷⁴, Ala³⁷⁵, Ala³⁷⁶, Gly³⁷⁷, Glu³⁷⁸, Cys³⁷⁹, Ala³⁸⁰-[Lys²⁴⁶,Ala²⁴⁷,Ser²⁴⁸,Gly²⁴⁹,Gly²⁵⁰,Asn³⁶⁴,Val⁴⁰⁷,Ser⁵¹⁵,Gln⁵⁹⁰, Gln⁶⁰⁶,Arg⁶¹³]exotoxine A (Pseudomonas aeruginosa)-(246-613)-peptide

cintredekina besudotox

toxina hIL13-PE38QQR (plásmido phuIL13-Tx)

C₂₂₃₄H₃₅₁₂N₆₅₀O₆₈₂S₁₀

davasaicinum

davasaicin

2-[4-(2-aminoethoxy)-3-methoxyphenyl]-N-[3-(3,4-dimethylphenyl)=propyl]acetamide

davasaïcine

2-[4-(2-aminoéthoxy)-3-méthoxyphényl]-N-[3-(3,4-diméthylphényl)=propyl]acétamide

davasaicina

2-[4-(2-aminoetoxi)-3-metoxifenil]-N-[3-(3,4-dimetilfenil)propil]=acetamida

C₂₂H₃₀N₂O₃

deferitrinum

deferitrin

(4S)-2-(2,4-dihydroxyphenyl)-4-methyl-4,5-dihydro-1,3-thiazole-4-carboxylic acid

déféritrine

acide (+)-(4S)-2-(2,4-dihydroxyphényl)-4-méthyl-4,5-dihydrothiazole-4-carboxylique

deferitrina

ácido (+)-(4S)-2-(2,4-dihidroxifenil)-4-metil-4,5-dihidrotiazol-4-carboxílico

C₁₁H₁₁NO₄S

delmitidum

delmitide

(2R)-2-[(2R)-2-{(2R)-2-[(2R)-2-{(2R)-2-[(2R)-2-(D-arginylamino)=hexanamido]hexanamido}hexanoyl-D-arginylamino]=hexanamido}hexanamido]hexanoylglycyl-D-tyrosinamide

delmitide

D-arginyl-(2R)-2-aminohexanoyl-(2R)-2-aminohexanoyl-(2R)-2-aminohexanoyl-D-arginyl-(2R)-2-aminohexanoyl-(2R)-2-aminohexanoyl-(2R)-2-aminohexanoylglycyl-D-tyrosinamide

delmitida

D-arginil-(2R)-2-aminohexanoil-(2R)-2-aminohexanoil-(2R)-2-aminohexanoil-D-arginil-(2R)-2-aminohexanoil-(2R)-2-aminohexanoil-(2R)-2-aminohexanoilglicil-D-tirosinamida

C₅₉H₁₀₅N₁₇O₁₁

deutolperisonum

deutolperisone

2-methyl-1-{4-([²H₃]methyl)[2,3,5,6-²H₄]phenyl}-3-(piperidin-1-yl)propan-1-one

deutolpérisone

(2RS)-2-méthyl-1-(4-(²H₃)méthyl(2,3,5,6-²H₄)phényl)-3-(pipéridin-1-yl)propan-1-one

deutolperisona

(2RS)-2-metil-1-(4-[²H₃]metil[2,3,5,6-²H₄]fenil)-3-(piperidin-1-il)propan-1-ona

C₁₆H₁₆²H₇NO

efipladibum

efipladib

4-(3-{5-chloro-2-[2-({[(3,4-dichlorophenyl)methyl]sulfonyl}amino)=ethyl]-1-(diphenylmethyl)-1H-indol-3-yl}propyl)benzoic acid

éfipladib

acide 4-[3-[5-chloro-2-[2-[[(3,4-dichlorobenzyl)sulfonyl]amino]éthyl]-1-(diphénylméthyl)-1H-indol-3-yl]propyl]benzoïque

efipladib

ácido 4-[3-[5-cloro-2-[2-[[(3,4-diclorobencil)sulfonil]amino]etil]-1-(difenilmetil)-1H-indol-3-il]propil]benzoico

C₄₀H₃₅Cl₃N₂O₄S

elomotecanum

elomotecan

(5R)-9-chloro-5-ethyl-5-hydroxy-10-methyl-12-[(4-methylpiperidin-1-yl)methyl]-1,4,5,13-tetrahydro-3H,15H-oxepino[3',4':6,7]=indolizino[1,2-b]quinoline-3,15-dione

élomotécan

(5R)-9-chloro-5-éthyl-5-hydroxy-10-méthyl-12-[(4-méthylpipéridin-1-yl)méthyl]-1,4,5,13-tétrahydro-3H,15H-oxépino[3',4':6,7]=indolizino[1,2-b]quinoléine-3,15-dione

elomotecán

(5R)-9-cloro-5-etil-5-hidroxi-10-metil-12-[(4-metilpiperidin-1-il)metil]-1,4,5,13-tetrahidro-3H,15H-oxepino[3',4':6,7]indolizino=[1,2-b]quinolina-3,15-diona

C₂₉H₃₂ClN₃O₄

embeconazolum

embeconazole

4-{(1E,3E)-4-(trans-5-{[(2R,3R)-3-(2,4-difluorophenyl)-3-hydroxy-4-(1H-1,2,4-triazol-1-yl)butan-2-yl]sulfanyl}-1,3-dioxan-2-yl)buta-1,3-dien-1-yl}-3-fluorobenzonitrile

embéconazole

(-)-4-[(1E,3E)-4-[trans-5-[[(1R,2R)-2-(2,4-difluorophényl)-2-hydroxy-1-méthyl-3-(1H-1,2,4-triazol-1-yl)propyl]sulfanyl]-1,3-dioxan-2-yl]buta-1,3-diényl]-3-fluorobenzonitrile

embeconazol

(-)-4-[(1E,3E)-4-[trans-5-[[(1R,2R)-2-(2,4-difluorofenil)-2-hidroxi-1-metil-3-(1H-1,2,4-triazol-1-il)propil]sulfanil]-1,3-dioxan-2-il]buta-1,3-dienil]-3-fluorobenzonitrilo

C₂₇H₂₅F₃N₄O₃S

epoetinum zeta

epoetin zeta

1-165-erythropoietin (human clone B03XA01), glycoform ζ

époétine zêta

1-165-érythropoïétine (humaine B03XA01), glycoforme ζ

epoetina zeta

1-165-eritropoyetina (humana B03XA01), glicoforma ζ

C₈₀₉H₁₃₀₁N₂₂₉O₂₄₀S₅

eritoranum

eritoran

2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-(octadec-11-enamido)-4-O-phosphono-β-D-glucopyranosyl-(1→6)-3-O-decyl-2-deoxy-2-(3-oxotetradecanamido)-α-D-glucopyranose1-(dihydrogen phosphate)

éritoran

dihydrogénophosphate de 3-O-décyl-2-désoxy-6-O-[2-désoxy-3-O-[(3R)-3-méthoxydécyl]-6-O-méthyl-2-[(11Z)-octadéc-11-énoylamino]-4-O-phosphono-β-D-glucopyranosyl]-2-[(3-oxotétradécanoyl)amino]-α-D-glucopyranosyle

eritorán

dihidrógenofosfato de 3-O-decil-2-desoxi-6-O-[2-desoxi-3-O-[(3R)-3-metoxidecil]-6-O-metil-2-[(11Z)-octadec-11-enamido]-4-O-fosfono-β-D-glucopiranosil]-2-(3-oxotetradecanamido)-α-D-glucopiranosilo

C₆₆H₁₂₆N₂O₁₉P₂

etalocibum

etalocib

2-(3-{3-[(5-ethyl-4'-fluoro-2-hydroxy-[1,1'-biphenyl]-4-yl)oxy]propoxy}-2-propylphenoxy)benzoic acid

étalocib

acide 2-[3-[3-[(5-éthyl-4'-fluoro-2-hydroxybiphényl-4-yl)oxy]propoxy]-2-propylphénoxy]benzoïque

etalocib

ácido 2-[3-[3-[(5-etil-4'-fluoro-2-hidroxibifenil-4-il)oxi]propoxi]-2-propilfenoxi]benzoico

C₃₃H₃₃FO₆

farampatorum

farampator

5-[(piperidin-1-yl)carbonyl]-2,1,3-benzooxadiazole

farampator

1-(2,1,3-benzoxadiazol-5-ylcarbonyl)pipéridine

farampator

1-(2,1,3-benzoxadiazol-5-ilcarbonil)piperidina

C₁₂H₁₃N₃O₂

forodesinum

forodesine

7-(5-amino-1,5-dideoxy-β-D-ribofuranos-1-yl)-1,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one

forodésine

(-)-7-[(2S,3S,4R,5R)-3,4-dihydroxy-5-(hydroxyméthyl)pyrrolidin-2-yl]-1,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one

forodesina

(-)-7-[(2S,3S,4R,5R)-3,4-dihidroxi-5-(hidroximetil)pirrolidin-2-il]-1,5-dihidro-4H-pirrolo[3,2-d]pirimidin-4-ona

C₁₁H₁₄N₄O₄

galsulfasum

galsulfase

N-acetylgalactosamine 4-sulfatase (human CSL4S-342 cell)

galsulfase

N-acétylgalactosamine 4-sulfatase (cellule humaine CSL4S-342)

galsulfasa

N-acetilgalactosamina 4-sulfatasa (célula humana CSL4S-342)

C₂₅₂₉H₃₈₄₃N₆₈₉O₇₁₆S₁₆

glucarpidasum

glucarpidase

recombinant glutamate carboxypeptidase (carboxypeptidase G2)

glucarpidase

[405-arginine]précurseur de la carboxypeptidase G2 de Pseudomonas (RS-16), enzyme à zinc dimérique, glutamate carboxypeptidase

glucarpidasa

glutamato carboxipeptidasa recombinante (carboxipeptidasa G2)

C₁₉₅₀H₃₁₅₇N₅₄₃O₅₉₉S₇ (monomer)

iboctadekinum

iboctadekin

a recombinant human interleukin-18 with 157 amino acids

iboctadékine

interleukine-18 humaine recombinante (157 aminoacides)

iboctadekina

interleukina-18 humana recombinante (157 aminoácidos)

C₈₀₁H₁₂₆₄N₂₁₂O₂₅₂S₁₀

icomucretum

icomucret

(5Z,8Z,11Z,13E,15S)-15-hydroxyicosa-5,8,11,13-tetraenoic acid

icomucret

acide (5Z,8Z,11Z,13E,15S)-15-hydroxyicosa-5,8,11,13-tétraénoïque

icomucret

ácido (5Z,8Z,11Z,13E,15S)-15-hidroxiicosa-5,8,11,13-tetraenoico

C₂₀H₃₂O₃

inotuzumabum ozogamicinum

inotuzumab ozogamicin

immunoglobulin G4, anti-(human CD22 (antigen)) (human-mouse monoclonal G544 heavy chain), disulfide with human-mouse monoclonal G544 K-chain, dimer, conjugate with methyl N-{(1R,4Z,8S,13E)-8-(4,6-dideoxy-4-{[(4-S-{4-[(6-deoxy-3-O-methyl-α-L-mannopyranosyl)oxy]-3-iodo-5,6-dimethoxy-2-methylbenzoyl}-4-thio-β-D-ribo-hexopyranosyl)oxy]amino}-2-O-[4-(N-ethylacetamido)-2,4-dideoxy-3-O-methyl-α-L-threo-pentopyranosyl]-β-D-glucopyranosyloxy)-13-[2-({4-[2-(1-{[4-(4-amino-4-oxobutyl)oxy]phenyl}ethylidene)hydrazinyl]-2-methyl-4-oxobutan-2-yl}disulfanyl)ethylidene]-1-hydroxy-11-oxobicyclo[7.3.1]trideca-4,9-diene-2,6-diyn-10-yl}carbamate

inotuzumab ozogamicine

N-[4-[4-[1-[[3-[[2-[(1R,4Z,8S,13E)-8-[[2-O-[4-(acétyléthylamino)-2,4-didésoxy-3-O-méthyl-α-L-thréo-pentopyranosyl]-4,6-didésoxy-4-[[[2,6-didésoxy-4-S-[4-[(6-désoxy-3-O-méthyl-α-L-mannopyranosyl)oxy]-3-iodo-5,6-diméthoxy-2-méthylbenzoyl]-4-thio-β-D-ribo-hexopyranosyl]oxy]amino]-β-D-glucopyranosyl]oxy]-1-hydroxy-10-[(méthoxycarbonyl)amino]-11-oxobicyclo[7.3.1]tridéca-4,9-diène-2,6-diyn-13-ylidène]éthyl]disulfanyl]-3-méthylbutanoyl]= diazanylidène]éthyl]phénoxy]butanoyl]immunoglobuline G4, anti-(antigène CD22 humain) dimère du disulfure entre la chaîne lourde et la chaîne K de l'anticorps monoclonal de souris G544 humanisé

inotuzumab ozogamicina

N-[4-[4-[1-[[3-[[2-[(1R,4Z,8S,13E)-8-[[2-O-[4-(acetiletilamino)-2,4-didesoxi-3-O-metil-α-L-treo-pentopiranosil]-4,6-didesoxi-4-[[[2,6-didesoxi-4-S-[4-[(6-desoxi-3-O-metil-α-L-manopiranosil)oxi]-3-iodo-5,6-dimetoxi-2-metilbenzoil]-4-tio-β-D-ribo-hexopiranosil]= oxi]amino]-p-D-glucopiranosil]oxi]-1-hidroxi-10-[(metoxicarbonil)=amino]-11-oxobiciclo[7.3.1]trideca-4,9-dieno-2,6-diino-13-ilideno]etil]disulfanil]-3-metilbutanoil]diazanilideno]etil]fenoxi]= butanoil]inmunoglobulina G4, anti-(antigeno CD22 humano) dimero del disulfuro entre la cadena pesada y la cadena K del anticuerpo monoclonal humanizado de ratón G544

C₆₅₁₈H₁₀₀₀₂N₁₇₃₈O₂₀₃₆S₄₂

Ig-NH₂ = inotuzumab

isalmadolum

isalmadol

3-{(1RS,2RS)-2-[(dimethylamino)methyl]-1-hydroxycyclohexyl}phenyl2-hydroxybenzoate

isalmadol

2-hydroxybenzoate de 3-[(1RS,2RS)-2-[(diméthylamino)méthyl]-1-hydroxycyclohexyl]phényle

isalmadol

2-hidroxibenzoato de 3-[(1RS,2RS)-2-[(dimetilamino)metil]-1-hidroxiciclohexil]fenilo

C₂₂H₂₇NO₄

ispinesibum

ispinesib

N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide

ispinésib

N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-méthylpropyl]-4-méthylbenzamide

ispinesib

N-(3-aminopropil)-N-[(1R)-1-(3-bencil-7-cloro-4-oxo-3,4-dihidroquinazolin-2-il)-2-metilpropil]-4-metilbenzamida

C₃₀H₃₃ClN₄O₂

levotofisopamum

levotofisopam

(5S)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiaxepine

lévotofisopam

(-)-(5S)-1-(3,4-diméthoxyphényl)-5-éthyl-7,8-diméthoxy-4-méthyl-5H-2,3-benzodiazépine

levotofisopam

(-)-(5S)-1-(3,4-dimetoxifenil)-5-etil-7,8-dimetoxi-4-metil-5H-2,3-benzodiazepina

C₂₂H₂₆N₂O₄

linaprazanum

linaprazan

8-{[(2,6-dimethylphenyl)methyl]amino}-N-(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide

linaprazan

8-[(2,6-diméthylbenzyl)amino]-N-(2-hydroxyéthyl)-2,3-diméthylimidazo[1,2-a]pyridine-6-carboxamide

linaprazán

8-[(2,6-dimetilbencil)amino]-N-(2-hidroxietil)-2,3-dimetilimidazo=[1,2-a]piridina-6-carboxamida

C₂₁H₂₆N₄O₂

morphini glucuronidum

morphine glucuronide

3-hydroxy-17-methyl-4,5α-epoxymorphin-7-en-6α-ylβ-D-glucopyranosiduronic acid

glucuronide de morphine

acide β-D-glucopyranosiduronique de 7,8-didéshydro-4,5α-époxy-3-hydroxy-17-méthylmorphinan-6α-yle

glucurónido de morfina

ácido β-D-glucopiranosidurónico de 7,8-dideshidro-4,5α-epoxi-3-hidroxi-17-metilmorfinan-6α-ilo

C₂₃H₂₇NO₉

naveglitazarum

naveglitazar

(2S)-2-methoxy-3-{4-[3-(4-phenoxyphenoxy)propoxy]phenyl}=propanoic acid

navéglitazar

acide (2S)-2-méthoxy-3-[4-[3-(4-phénoxyphénoxy)propoxy]phényl]=propanoïque

naveglitazar

ácido (2S)-2-metoxi-3-[4-[3-(4-fenoxifenoxi)propoxi]fenil]propanoico

C₂₅H₂₆O₆

omocianinum

omocianine

2-{(1E,3E,5E)-7-[(2E)-3,3-dimethyl-5-sulfonato-1-(2-sulfonatoethyl)-1,3-dihydro-2H-indol-2-ylidene]-4-methylhepta-1,3,5-trienyl}-3,3-dimethyl-1-(2-sulfonatoethyl)-3H-indolium-5-sulfonate

omocianine

trihydrogéno-2-[(1E,3E,5E)-7-[(2E)-3,3-diméthyl-5-sulfonato-1-(2-sulfonatoéthyl)-1,3-dihydro-2H-indol-2-ylidène]-4-méthylhepta-1,3,5-triényl]-3,3-diméthyl-1-(2-sulfonatoéthyl)-3H-indolium-5-sulfonate

omocianina

trihidrógeno-2-[(1E,3E,5E)-7-[(2E)-3,3-dimetil-5-sulfonato-1-(2-sulfonatoetil)-1,3-dihidro-2H-indol-2-ilideno]-4-metilhepta-1,3,5-trienil]-3,3-dimetil-1-(2-sulfonatoetil)-3H-indolio-5-sulfonato

C₃₂H₃₈N₂O₁₂S₄

peliglitazarum

peliglitazar

N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}ethyl]glycine

péliglitazar

acide [[(4-méthoxyphénoxy)carbonyl][(1S)-1-[4-[2-(5-méthyl-2-phényloxazol-4-yl)éthoxy]phényl]éthyl]amino]acétique

peliglitazar

ácido [[(4-metoxifenoxi)carbonil][(1S)-1-[4-[2-(5-metil-2-feniloxazol-4-il)etoxi]fenil]etil]amino]acético

C₃₀H₃₀N₂O₇

pemaglitazarum

pemaglitazar

(2S)-4-[(2-methylphenyl)sulfanyl]-2-[4-(trifluromethyl)phenoxy]=butanoic acid

pémaglitazar

(-)-acide (2S)-4-[(2-méthylphényl)sulfanyl]-2-[4-(trifluorométhyl)=phénoxy]butanoïque

pemaglitazar

(-)-ácido (2S)-4-[(2-metilfenil)sulfanil]-2-[4-(trifluorometil)fenoxi]=butanoico

C₁₈H₁₇F₃O₃S

perflisobutanum

perflisobutane

1,1,1,2,3,3,3-heptafluoro-2-(trifluoromethyl)propane

perflisobutane

1,1,1,2,3,3,3-heptafluoro-2-(trifluorométhyl)propane

perflisobutano

1,1,1,2,3,3,3-heptafluoro-2-(trifluorometil)propano

C₄F₁₀

piclozotanum

piclozotan

3-chloro-4-[4-(1',2',3',6'-tetrahydro-[2,4'-bipyridin]-1'-yl)butyl]-1,4-benzoxazepin-5(4H)-one

piclozotan

3-chloro-4-[4-(3',6'-dihydro-2,4'-bipyridinyl-1'(2'H)-yl)butyl]-1,4-benzoxazépin-5(4H)-one

piclozotán

3-cloro-4-[4-(3',6'-dihidro-2,4'-bipiridinil-1'(2'H)-il)butil]-1,4-benzoxazepin-5(4H)-ona

C₂₃H₂₄ClN₃O₂

pralatrexatum

pralatrexate

N-{4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}-L-glutamic acid

pralatrexate

acide (2S)-2-[[4-[(1RS)-1-[(2,4-diaminoptéridin-6-yl)méthyl]but-3-ynyl]benzoyl]amino]pentanedioïque

pralatrexato

ácido (2S)-2-[[4-[(1RS)-1-[(2,4-diaminopteridin-6-il)metil]but-3-inil]benzoil]amino]pentanodioico

C₂₃H₂₃N₇O₅

radoterminum

radotermin

growth differentiation factor 5 (human), homodimer

radotermine

facteur 5 humain de différenciation de la croissance, homodimère produit par E. coli

radotermina

factor 5 humano de diferenciación del crecimiento homodímero producido por E. coli

C₁₁₈₄H₁₈₄₄N₃₃₀O₃₅₀S₂₂

raxibacumabum

raxibacumab

immunoglobulin G1, anti-(anthrax protective antigen) (human monoclonal PA heavy chain), disulfide with human monoclonal PA λ-chain, dimer

raxibacumab

immunoglobuline G1, anti-(antigen protecteur de l'anthrax), dimère du disulfure entre la chaine lourde et la chaîne λ de l'anticorps monoclonal humain PA

raxibacumab

inmunoglobulina G1, anti-(antígeno protector del antrax), dímero del disulfuro entre la cadena pesada y la cadena λ del anticuerpo monoclonal humano PA

C₆₃₂₀H₉₇₉₄N₁₇₀₂O₁₉₉₈S₄₂

rimeporidum

rimeporide

N-(aminoiminomethyl)-4,5-bis(methanesulfonyl)-2-methylbenzamide

riméporide

N-carbamimidoyl-2-méthyl-4,5-bis(méthylsulfonyl)benzamide

rimeporida

N-carbamimidoil-2-metil-4,5-bis(metilsulfonil)benzamida

C₁₁H₁₅N₃O₅S₂

saxagliptinum

saxagliptin

(1S,3S,5S)-2-{(2S)-2-amino-2-(3-hydroxyadamantan-1-yl)acetyl}-2-azabicyclo[3.1.0]hexane-3-carbonitrile

saxagliptine

(1S,3S,5S)-2-[(2S)-amino(3-hydroxytricyclo[3.3.1.1^3,7]déc-1-yl)=acétyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile

saxagliptina

(1S,3S,5S)-2-[(2S)-amino(3-hidroxitriciclo[3.3.1.1^3,7]dec-1-il)acetil]-2-azabiciclo[3.1.0]hexano-3-carbonitrilo

C₁₈H₂₅N₃O₂

seliciclibum

seliciclib

(2R)-2-{[6-benzylamino-9-(propan-2-yl)-9H-purin-2-yl]amino}butan-1-ol

séliciclib

(-)-(2R)-2-[[6-(benzylamino)-9-(1-méthyléthyl)-9H-purin-2-yl]amino]=butan-1-ol

seliciclib

(-)-(2R)-2-[[6-(bencilamino)-9-(1-metiletil)-9H-purin-2-il]amino]butan-1-ol

C₁₉H₂₆N₆O

sugammadexum

sugammadex

cyclooctakis-(1?4)-[6-S-(2-carboxyethyl)-6-thio-α-D-glucopyranosyl]

sugammadex

cyclooctakis-(1?4)-[6-S-(2-carboxyéthyl)-6-thio-α-D-glucopyranosyl]

sugammadex

ciclooctakis-(1?4)-[6-S-(2-carboxietil)-6-tio-α-D-glucopiranosil]

C₇₂H₁₁₂O₄₈S₈

talabostatum

talabostat

{(2R)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl}boronic acid

talabostat

acide [(2R)-1-[(2S)-2-amino-3-méthylbutanoyl]pyrrolidin-2-yl]=boronique

talabostat

ácido [(2R)-1-[(2S)-2-amino-3-metilbutanoil]pirrolidin-2-il]borónico

C₉H₁₉BN₂O₃

talactoferrinum alfa

talactoferrin alfa

lactoferrin (recombinant human LF00)

talactoferrine alfa

[11-L-thréonine,29-L-arginine]lactotransferrine humaine produite parAspergillus niger var. awamori

talactoferrina alfa

[11-L-treonina,29-L-arginina]lactotransferrina humana producida porAspergillus niger var. awamori

C₃₃₄₅H₅₂₁₅N₉₆₃O₁₀₁₅S₃₇ (peptide)

talaglumetadum

talaglumetad

(1S,2S,5R,6S)-2-[(2S)-2-aminopropanamido]bicyclo[3.1.0]hexane-2,6-dicarboxylic acid

talaglumétad

acide (1S,2S,5R,6S)-2-[[(2S)-2-aminopropanoyl]amino]=bicyclo[3.1.0]hexane-2,6-dicarboxylique

talaglumetad

ácido (1S,2S,5R,6S)-2-[[(2S)-2-aminopropanoil]amino]=biciclo[3.1.0]hexano-2,6-dicarboxílico

C₁₁H₁₆N₂O₅

tanogitranum

tanogitran

N-[(2R)-2-{2-[(4-carbamimidoylanilino)methyl]-1-methyl-1H-benzimidazol-5-yl}-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl]glycine

tanogitran

acide [[(1R)-1-[2-[[(4-carbamimidoylphényl)amino]méthyl]-1-méthyl-1H-benzimidazol-5-yl]-1-méthyl-2-oxo-2-(pyrrolidin-1-yl)éthyl]= amino]acétique

tanogitrán

ácido [[(1R)-1-[2-[[(4-carbamimidoilfenil)amino]metil]-1-metil-1H-bencimidazol-5-il]-1-metil-2-oxo-2-(pirrolidin-1-il)etil]amino]= acético

C₂₅H₃₁N₇O₃

tefibazumabum

tefibazumab

immunoglobulin G1, anti-(Staphylococcus aureus protein ClfA (clumping factor A)) (human-Mus musculus monoclonal Aurexis heavy chain), disulfide with human-Mus musculus monoclonal Aurexis κ-chain, dimer

téfibazumab

immunoglobuline G1, anti-(protéine ClfA (facteur A d'agrégation) de Staphylococcus aureus) dimère du disulfure entre la chaîne lourde et la chaîne κ de l'anticorps monoclonal Mus-musculus Aurexis humanisé

tefibazumab

inmunoglobulina G1, anti-(proteína ClfA (factor A de agregación) de Staphylococcus aureus) dimero del disulfuro entre la cadena pesada y la cadena κ del anticuerpo monoclonal humano Mus-musculus Aurexis

C₆₅₄₈H₁₀₁₂₂N₁₇₃₀O₂₀₃₄S₄₄

temsirolimusum

temsirolimus

(1R,2R,4S)-4-{(2R)-2-(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34 a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]= oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate

temsirolimus

3-hydroxy-2-(hydroxyméthyl)-2-méthylpropanoate de (1R,2R,4S)-4-[(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S, 26R,27R,34aS)-9,27-dihydroxy-10,21-diméthoxy-6,8,12,14,20,26-hexaméthyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22, 23,24,25,26,27,28,29,31,32,33,34,34a-tétracosahydro-23,27-époxy-3H-pyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propyl]-2-méthoxycyclohexyle

temsirolimus

3-hidroxi-2-(hidroximetil)-2-metilpropanoato de (1R,2R,4S)-4-[(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihidroxi-10,21-dimetoxi-6,8,12,14,20,26-hexametil-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24, 25,26,27,28,29,31,32,33,34,34a-tetracosahidro-23,27-epoxi-3H-pirido[2,1-c][1,4]oxazaciclohentriacontin-3-il]propil]-2-metoxiciclohexilo

C₅₆H₈₇NO₁₆

tetomilastum

tetomilast

6-[2-(3,4-diethoxyphenyl)-1,3-thiazol-4-yl]pyridine-2-carboxylic acid

tétomilast

acide 6-[2-(3,4-diéthoxyphényl)thiazol-4-yl]pyridine-2-carboxylique

tetomilast

ácido 6-[2-(3,4-dietoxifenil)tiazol-4-il]piridina-2-carboxílico

C₁₉H₁₈N₂O₄S

thrombomodulinum alfa

thrombomodulin alfa

1-498-thrombomodulin (human clone TMP26/TMJ1 protein moiety reduced)

thrombomoduline alfa

[473-valine]précurseur de la thrombomoduline humaine-(19-516)-peptide (protéine soluble)

trombomodulina alfa

[473-valina]precursor de la trombomodulina humana-(19-516)-péptido (proteína soluble)

C₂₂₃₀H₃₃₅₇N₆₃₃O₇₁₈S₅₀

p. 351

suprimáse

insértese

temserolimusum

temsirolimusum

temserolimus

temsirolimus

p. 354

thrombomodulinum alfa

thrombomodulin alfa

replace the graphic formula by the following:

thrombomoduline alfa

remplacer la formule développée par:

trombomodulina alfa

sustitúyase la fórmula desarrollada por:

p. 6

nosiheptidum nosiheptide

replace the molecular formula by the following:

nosiheptide

remplacer la formule brute par:

nosiheptida

sustitúyase la fórmula empírica por:

C₅₁H₄₃N₁₃O₁₂S₆

p. 5

suprimase

insértese

bosentano

bosentán

p. 252

suprimáse

insértese

esoxybutynina

esoxibutinina

p. 258

suprimáse

insértese

ramelteòn

ramelteón

p. 74

dasantafilum

dasantafil

replace the chemical name by the following:

7-(3-bromo-4-methoxyphenylmethyl)-1-ethyl-8-{[(1R,2R)-2-hydroxycyclopentyl]=amino}-3-(2-hydroxyethyl)-3,7-dihydro-1H-purine-2,6-dione

p. 75

deluceminum

delucemine

replace the molecular formula by the following:

délucémine

remplacer la formule brute par:

delucemina

sustitúyase la fórmula empírica por:

C₁₆H₁₇F₂N

p. 84

maravirocum

maraviroc

replace the chemical name by the following:

4,4-difluoro-N-[(1S)-3-{(1R,3s,5S)-3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl}-1-phenylpropyl]cyclohexanecarboxamide

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances will be reproduced in proposed INN lists only.

Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques seront publiés seulement dans les listes des DCI proposées.

El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas aparece solamente en las listas de DCI propuestas.